CMBA
FULC icon

C.M. Bidwell & Associates’s Fulcrum Therapeutics FULC Stock Holding History

C.M. Bidwell & Associates’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-117
Closed -$550 – 478
2024
Q4 		$550 Buy
+117
New +$432 ﹤0.01% 451

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

C.M. Bidwell & Associates's FULC Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Fulcrum Therapeutics (FULC) in Q1 2025, closing a stake of 117 shares — an estimated $550 sold.

C.M. Bidwell & Associates first reported a position in FULC in Q4 2024 and held it in 1 quarter. The position peaked at $550 in Q4 2024. 117 funds tracked by Wall St. Rank hold FULC as of Q1 2025.

  • C.M. Bidwell & Associates reported no remaining Fulcrum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 117 Fulcrum Therapeutics shares in Q1 2025, an estimated $550.
  • C.M. Bidwell & Associates first reported a position in Fulcrum Therapeutics in Q4 2024 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Fulcrum Therapeutics position peaked at $550 in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.